Details for this material are provided in the NIH AIDS Reagent Program Catalog (Catalog# 341): https://www.aidsreagent.org/reagentdetail.cfm?t=cell_lines&id=152.

Anthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided):

1. PA.

Ccr9^-/- mice may be useful for studying the role of CCR9 in T lymphocyte development and migration.

Mice will be distributed by The Jackson Laboratory; details about this mouse strain (Stock No. 027041) may be found at https://www.jax.org/strain/027041.

Expression, purification, and validation of anthrax toxin proteins.

Loa loa microfilarial-specific peptide sequences that could be used as a research material as well as for development of immunoassays for detection of Loa loa microfilaremia.

Details for these materials may be found in the NIH AIDS Reagent Program Catalog –

• RSC3 (Catalog# 12042): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=214
• RSC3 delta371I (Catalog# 12043): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=146
• RSC3 delta371I/P363N (Catalog# 12362):

Mutation in gene A34R can regulate the release of progeny virions from the surface of parental cells.

Reagents particularly useful in configuring multiplex assays for simultaneous measurement and quantification of multiple eosinophil granule proteins and for immunohistochemistry. Ultimately these reagents may be used as diagnostics for many eosinophil-mediated disorders.

B. anthracis strains BH480; plasmids encoding anthrax edema factor (EF) variants pSJ136EFOS, pSJ 136EFA and pSJ 136EFR.

Human parainfluenza virus (hPIV) is an RNA-based paramyxovirus that causes respiratory infections in children and adults. There are four serotypes that can result in a myriad of diseases of the respiratory tract including croup, bronchitis, and pneumonia (Mao et al., 2012). hPIV is a leading cause of respiratory tract infection and hospitalization among children under 5, only surpassed by the respiratory syncytial virus (RSV). Currently, there are limited treatment options and no approved vaccines.